In Search Of A Stimulant Use Disorder Treatment: ‘We’ve Been Doing It Wrong’
US FDA official questions whether problem is due to population selection, outcome measures, or study duration. Potential endpoints include change in disease status as measured by DSM-5 criteria, cognitive function and quality of life, experts say.
You may also be interested in...
Unlike prior plans, the FDA’s new substance abuse framework is intended to deal with stimulant and benzodiazepine use disorders, in addition to opioid abuse.
The move should increase the visibility of the FDA’s wide-ranging, and widely criticized, opioid epidemic response.
Robert Califf’s first tenure as US FDA Commissioner was decidedly anti-climactic. His return trip – assuming the Senate confirms him – will be potentially transformational: he will be the leader that defines what FDA is after COVID.